---
document_datetime: 2025-12-02 05:14:51
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/pomalidomide-viatris.html
document_name: pomalidomide-viatris.html
version: success
processing_time: 0.1264811
conversion_datetime: 2025-12-24 04:20:03.91609
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Pomalidomide Viatris

[RSS](/en/individual-human-medicine.xml/97820)

##### Authorised

This medicine is authorised for use in the European Union

pomalidomide Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Pomalidomide Viatris](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Pomalidomide Viatris is a cancer medicine used to treat multiple myeloma (a cancer of the bone marrow). It is used in combination with bortezomib (another cancer medicine) and dexamethasone (an anti-inflammatory medicine) in adults who have received at least one treatment including lenalidomide (another cancer medicine).

It is also used in combination with dexamethasone in adults who have received at least two prior therapies, including both lenalidomide and bortezomib, and whose disease has worsened.

Pomalidomide Viatris is a 'generic medicine'. This means that Pomalidomide Viatris contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU. The reference medicine for Pomalidomide Viatris is Imnovid. For more information on generic medicines, see the question-and-answer document [here](https://www.ema.europa.eu/en/documents/other/questions-and-answers-generic-medicines_en.pdf) .

Pomalidomide Viatris contains the active substance pomalidomide

Expand section

Collapse section

## How is Pomalidomide Viatris used?

Treatment with Pomalidomide Viatris must be started and supervised by a doctor experienced in treating multiple myeloma. The medicine can only be obtained with a medical prescription.

Pomalidomide Viatris is available as capsules (1, 2, 3 and 4 mg). It is taken in the first 2 weeks of 3-week treatment cycles, when given in combination with bortezomib and dexamethasone, and in the first 3 weeks of 4-week treatment cycles when given in combination with dexamethasone only. The recommended starting dose is 4 mg once a day, taken at the same time each day.

Treatment with Pomalidomide Viatris may need to be interrupted or stopped, or the dose reduced, if the disease gets worse or certain side effects occur. For more information about using Pomalidomide Viatris, see the package leaflet or contact your doctor or pharmacist.

## How does Pomalidomide Viatris work?

The active substance in Pomalidomide Viatris, pomalidomide, is an immunomodulating agent. This means that it affects the activity of the immune system (the body's natural defences). Pomalidomide works in a number of ways in multiple myeloma, similarly to other immunomodulating medicines such as lenalidomide and thalidomide: it blocks the development of tumour cells, prevents the growth of blood vessels within tumours and also stimulates some specialised cells of the immune system to attack the tumour cells.

## How has Pomalidomide Viatris been studied?

Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Imnovid, and do not need to be repeated for Pomalidomide Viatris.

As for every medicine, the company provided studies on the quality of Pomalidomide Viatris. The company also carried out studies that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Pomalidomide Viatris?

Because Pomalidomide Viatris is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Pomalidomide Viatris authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Pomalidomide Viatris has been shown to have comparable quality and to be bioequivalent to the reference medicine. Therefore, the Agency's view was that, as for reference medicine, the benefits of Pomalidomide Viatris outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Pomalidomide Viatris?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Pomalidomide Viatris have been included in the summary of product characteristics and the package leaflet.

Any additional measures in place for reference medicine, such as a patient card with key safety information, also apply to Pomalidomide Viatris where appropriate.

As for all medicines, data on the use of Pomalidomide Viatris are continuously monitored. Suspected side effects reported with Pomalidomide Viatris are carefully evaluated and any necessary action taken to protect patients.

## Other information about Pomalidomide Viatris

Pomalidomide Viatris received a marketing authorisation valid throughout the EU on 16 February 2024.

Pomalidomide Viatris : EPAR - Medicine overview

Reference Number: EMA/48254/2024

English (EN) (123.97 KB - PDF)

**First published:** 12/03/2024

[View](/en/documents/overview/pomalidomide-viatris-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-245)

български (BG) (167.17 KB - PDF)

**First published:**

12/03/2024

[View](/bg/documents/overview/pomalidomide-viatris-epar-medicine-overview_bg.pdf)

español (ES) (145.57 KB - PDF)

**First published:**

12/03/2024

[View](/es/documents/overview/pomalidomide-viatris-epar-medicine-overview_es.pdf)

čeština (CS) (167.62 KB - PDF)

**First published:**

12/03/2024

[View](/cs/documents/overview/pomalidomide-viatris-epar-medicine-overview_cs.pdf)

dansk (DA) (143.72 KB - PDF)

**First published:**

12/03/2024

[View](/da/documents/overview/pomalidomide-viatris-epar-medicine-overview_da.pdf)

Deutsch (DE) (148.05 KB - PDF)

**First published:**

12/03/2024

[View](/de/documents/overview/pomalidomide-viatris-epar-medicine-overview_de.pdf)

eesti keel (ET) (141.53 KB - PDF)

**First published:**

12/03/2024

[View](/et/documents/overview/pomalidomide-viatris-epar-medicine-overview_et.pdf)

ελληνικά (EL) (168.94 KB - PDF)

**First published:**

12/03/2024

[View](/el/documents/overview/pomalidomide-viatris-epar-medicine-overview_el.pdf)

français (FR) (136.31 KB - PDF)

**First published:**

12/03/2024

[View](/fr/documents/overview/pomalidomide-viatris-epar-medicine-overview_fr.pdf)

hrvatski (HR) (163.38 KB - PDF)

**First published:**

12/03/2024

[View](/hr/documents/overview/pomalidomide-viatris-epar-medicine-overview_hr.pdf)

italiano (IT) (144.75 KB - PDF)

**First published:**

12/03/2024

[View](/it/documents/overview/pomalidomide-viatris-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (182.48 KB - PDF)

**First published:**

12/03/2024

[View](/lv/documents/overview/pomalidomide-viatris-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (165.03 KB - PDF)

**First published:**

12/03/2024

[View](/lt/documents/overview/pomalidomide-viatris-epar-medicine-overview_lt.pdf)

magyar (HU) (167.37 KB - PDF)

**First published:**

12/03/2024

[View](/hu/documents/overview/pomalidomide-viatris-epar-medicine-overview_hu.pdf)

Malti (MT) (167.8 KB - PDF)

**First published:**

12/03/2024

[View](/mt/documents/overview/pomalidomide-viatris-epar-medicine-overview_mt.pdf)

Nederlands (NL) (145.25 KB - PDF)

**First published:**

12/03/2024

[View](/nl/documents/overview/pomalidomide-viatris-epar-medicine-overview_nl.pdf)

polski (PL) (169.15 KB - PDF)

**First published:**

12/03/2024

[View](/pl/documents/overview/pomalidomide-viatris-epar-medicine-overview_pl.pdf)

português (PT) (145.6 KB - PDF)

**First published:**

12/03/2024

[View](/pt/documents/overview/pomalidomide-viatris-epar-medicine-overview_pt.pdf)

română (RO) (163.28 KB - PDF)

**First published:**

12/03/2024

[View](/ro/documents/overview/pomalidomide-viatris-epar-medicine-overview_ro.pdf)

slovenčina (SK) (165.44 KB - PDF)

**First published:**

12/03/2024

[View](/sk/documents/overview/pomalidomide-viatris-epar-medicine-overview_sk.pdf)

slovenščina (SL) (162.14 KB - PDF)

**First published:**

12/03/2024

[View](/sl/documents/overview/pomalidomide-viatris-epar-medicine-overview_sl.pdf)

Suomi (FI) (131.83 KB - PDF)

**First published:**

12/03/2024

[View](/fi/documents/overview/pomalidomide-viatris-epar-medicine-overview_fi.pdf)

svenska (SV) (142.63 KB - PDF)

**First published:**

12/03/2024

[View](/sv/documents/overview/pomalidomide-viatris-epar-medicine-overview_sv.pdf)

## Product information

Pomalidomide Viatris : EPAR - Product information

English (EN) (882.55 KB - PDF)

**First published:** 18/12/2024

**Last updated:** 06/01/2025

[View](/en/documents/product-information/pomalidomide-viatris-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-864)

български (BG) (898.27 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/bg/documents/product-information/pomalidomide-viatris-epar-product-information_bg.pdf)

español (ES) (784.14 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/es/documents/product-information/pomalidomide-viatris-epar-product-information_es.pdf)

čeština (CS) (781.39 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/cs/documents/product-information/pomalidomide-viatris-epar-product-information_cs.pdf)

dansk (DA) (775.49 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/da/documents/product-information/pomalidomide-viatris-epar-product-information_da.pdf)

Deutsch (DE) (824.2 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/de/documents/product-information/pomalidomide-viatris-epar-product-information_de.pdf)

eesti keel (ET) (877.31 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/et/documents/product-information/pomalidomide-viatris-epar-product-information_et.pdf)

ελληνικά (EL) (908.44 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/el/documents/product-information/pomalidomide-viatris-epar-product-information_el.pdf)

français (FR) (890.58 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/fr/documents/product-information/pomalidomide-viatris-epar-product-information_fr.pdf)

hrvatski (HR) (837.28 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/hr/documents/product-information/pomalidomide-viatris-epar-product-information_hr.pdf)

íslenska (IS) (779.02 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/is/documents/product-information/pomalidomide-viatris-epar-product-information_is.pdf)

italiano (IT) (757.34 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/it/documents/product-information/pomalidomide-viatris-epar-product-information_it.pdf)

latviešu valoda (LV) (811.35 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/lv/documents/product-information/pomalidomide-viatris-epar-product-information_lv.pdf)

lietuvių kalba (LT) (903.74 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/lt/documents/product-information/pomalidomide-viatris-epar-product-information_lt.pdf)

magyar (HU) (876.77 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/hu/documents/product-information/pomalidomide-viatris-epar-product-information_hu.pdf)

Malti (MT) (821.53 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/mt/documents/product-information/pomalidomide-viatris-epar-product-information_mt.pdf)

Nederlands (NL) (799.3 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/nl/documents/product-information/pomalidomide-viatris-epar-product-information_nl.pdf)

norsk (NO) (685.2 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/no/documents/product-information/pomalidomide-viatris-epar-product-information_no.pdf)

polski (PL) (852.02 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/pl/documents/product-information/pomalidomide-viatris-epar-product-information_pl.pdf)

português (PT) (821.67 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/pt/documents/product-information/pomalidomide-viatris-epar-product-information_pt.pdf)

română (RO) (827.26 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/ro/documents/product-information/pomalidomide-viatris-epar-product-information_ro.pdf)

slovenčina (SK) (904.86 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/sk/documents/product-information/pomalidomide-viatris-epar-product-information_sk.pdf)

slovenščina (SL) (793.58 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/sl/documents/product-information/pomalidomide-viatris-epar-product-information_sl.pdf)

Suomi (FI) (838.55 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/fi/documents/product-information/pomalidomide-viatris-epar-product-information_fi.pdf)

svenska (SV) (782.13 KB - PDF)

**First published:**

18/12/2024

**Last updated:**

06/01/2025

[View](/sv/documents/product-information/pomalidomide-viatris-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0002 16/12/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Pomalidomide Viatris : EPAR - All authorised presentations

English (EN) (60.23 KB - PDF)

**First published:** 12/03/2024

[View](/en/documents/all-authorised-presentations/pomalidomide-viatris-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-176)

български (BG) (73.34 KB - PDF)

**First published:**

12/03/2024

[View](/bg/documents/all-authorised-presentations/pomalidomide-viatris-epar-all-authorised-presentations_bg.pdf)

español (ES) (63.76 KB - PDF)

**First published:**

12/03/2024

[View](/es/documents/all-authorised-presentations/pomalidomide-viatris-epar-all-authorised-presentations_es.pdf)

čeština (CS) (65.81 KB - PDF)

**First published:**

12/03/2024

[View](/cs/documents/all-authorised-presentations/pomalidomide-viatris-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (65.33 KB - PDF)

**First published:**

12/03/2024

[View](/da/documents/all-authorised-presentations/pomalidomide-viatris-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (50.91 KB - PDF)

**First published:**

12/03/2024

[View](/de/documents/all-authorised-presentations/pomalidomide-viatris-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (63.47 KB - PDF)

**First published:**

12/03/2024

[View](/et/documents/all-authorised-presentations/pomalidomide-viatris-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (65.96 KB - PDF)

**First published:**

12/03/2024

[View](/el/documents/all-authorised-presentations/pomalidomide-viatris-epar-all-authorised-presentations_el.pdf)

français (FR) (62.19 KB - PDF)

**First published:**

12/03/2024

[View](/fr/documents/all-authorised-presentations/pomalidomide-viatris-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (60.72 KB - PDF)

**First published:**

12/03/2024

[View](/hr/documents/all-authorised-presentations/pomalidomide-viatris-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (63.79 KB - PDF)

**First published:**

12/03/2024

[View](/is/documents/all-authorised-presentations/pomalidomide-viatris-epar-all-authorised-presentations_is.pdf)

italiano (IT) (60.33 KB - PDF)

**First published:**

12/03/2024

[View](/it/documents/all-authorised-presentations/pomalidomide-viatris-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (65.2 KB - PDF)

**First published:**

12/03/2024

[View](/lv/documents/all-authorised-presentations/pomalidomide-viatris-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (65.02 KB - PDF)

**First published:**

12/03/2024

[View](/lt/documents/all-authorised-presentations/pomalidomide-viatris-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (67.67 KB - PDF)

**First published:**

12/03/2024

[View](/hu/documents/all-authorised-presentations/pomalidomide-viatris-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (66.48 KB - PDF)

**First published:**

12/03/2024

[View](/mt/documents/all-authorised-presentations/pomalidomide-viatris-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (63.09 KB - PDF)

**First published:**

12/03/2024

[View](/nl/documents/all-authorised-presentations/pomalidomide-viatris-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (64.66 KB - PDF)

**First published:**

12/03/2024

[View](/no/documents/all-authorised-presentations/pomalidomide-viatris-epar-all-authorised-presentations_no.pdf)

polski (PL) (63.79 KB - PDF)

**First published:**

12/03/2024

[View](/pl/documents/all-authorised-presentations/pomalidomide-viatris-epar-all-authorised-presentations_pl.pdf)

português (PT) (61.74 KB - PDF)

**First published:**

12/03/2024

[View](/pt/documents/all-authorised-presentations/pomalidomide-viatris-epar-all-authorised-presentations_pt.pdf)

română (RO) (63.43 KB - PDF)

**First published:**

12/03/2024

[View](/ro/documents/all-authorised-presentations/pomalidomide-viatris-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (65.2 KB - PDF)

**First published:**

12/03/2024

[View](/sk/documents/all-authorised-presentations/pomalidomide-viatris-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (61.26 KB - PDF)

**First published:**

12/03/2024

[View](/sl/documents/all-authorised-presentations/pomalidomide-viatris-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (62.95 KB - PDF)

**First published:**

12/03/2024

[View](/fi/documents/all-authorised-presentations/pomalidomide-viatris-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (63.09 KB - PDF)

**First published:**

12/03/2024

[View](/sv/documents/all-authorised-presentations/pomalidomide-viatris-epar-all-authorised-presentations_sv.pdf)

Pomalidomide Viatris : EPAR - Conditions imposed on member states for safe and effective use - Annex related to Art. 127a

English (EN) (262.16 KB - PDF)

**First published:** 12/03/2024

[View](/en/documents/conditions-member-states/pomalidomide-viatris-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_en.pdf)

[Other languages (24)](#file-language-dropdown-672)

български (BG) (228.13 KB - PDF)

**First published:**

12/03/2024

[View](/bg/documents/conditions-member-states/pomalidomide-viatris-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_bg.pdf)

español (ES) (119.61 KB - PDF)

**First published:**

12/03/2024

[View](/es/documents/conditions-member-states/pomalidomide-viatris-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_es.pdf)

čeština (CS) (216.31 KB - PDF)

**First published:**

12/03/2024

[View](/cs/documents/conditions-member-states/pomalidomide-viatris-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_cs.pdf)

dansk (DA) (132.77 KB - PDF)

**First published:**

12/03/2024

[View](/da/documents/conditions-member-states/pomalidomide-viatris-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_da.pdf)

Deutsch (DE) (171.55 KB - PDF)

**First published:**

12/03/2024

[View](/de/documents/conditions-member-states/pomalidomide-viatris-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_de.pdf)

eesti keel (ET) (183.4 KB - PDF)

**First published:**

12/03/2024

[View](/et/documents/conditions-member-states/pomalidomide-viatris-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_et.pdf)

ελληνικά (EL) (184.48 KB - PDF)

**First published:**

12/03/2024

[View](/el/documents/conditions-member-states/pomalidomide-viatris-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_el.pdf)

français (FR) (220.72 KB - PDF)

**First published:**

12/03/2024

[View](/fr/documents/conditions-member-states/pomalidomide-viatris-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_fr.pdf)

hrvatski (HR) (216.38 KB - PDF)

**First published:**

12/03/2024

[View](/hr/documents/conditions-member-states/pomalidomide-viatris-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_hr.pdf)

íslenska (IS) (161.79 KB - PDF)

**First published:**

12/03/2024

[View](/is/documents/conditions-member-states/pomalidomide-viatris-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_is.pdf)

italiano (IT) (192 KB - PDF)

**First published:**

12/03/2024

[View](/it/documents/conditions-member-states/pomalidomide-viatris-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_it.pdf)

latviešu valoda (LV) (180.13 KB - PDF)

**First published:**

12/03/2024

[View](/lv/documents/conditions-member-states/pomalidomide-viatris-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_lv.pdf)

lietuvių kalba (LT) (203.91 KB - PDF)

**First published:**

12/03/2024

[View](/lt/documents/conditions-member-states/pomalidomide-viatris-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_lt.pdf)

magyar (HU) (217.53 KB - PDF)

**First published:**

12/03/2024

[View](/hu/documents/conditions-member-states/pomalidomide-viatris-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_hu.pdf)

Malti (MT) (172.14 KB - PDF)

**First published:**

12/03/2024

[View](/mt/documents/conditions-member-states/pomalidomide-viatris-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_mt.pdf)

Nederlands (NL) (149.61 KB - PDF)

**First published:**

12/03/2024

[View](/nl/documents/conditions-member-states/pomalidomide-viatris-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_nl.pdf)

norsk (NO) (66.01 KB - PDF)

**First published:**

12/03/2024

[View](/no/documents/conditions-member-states/pomalidomide-viatris-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_no.pdf)

polski (PL) (220.79 KB - PDF)

**First published:**

12/03/2024

[View](/pl/documents/conditions-member-states/pomalidomide-viatris-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_pl.pdf)

português (PT) (127.61 KB - PDF)

**First published:**

12/03/2024

[View](/pt/documents/conditions-member-states/pomalidomide-viatris-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_pt.pdf)

română (RO) (186.51 KB - PDF)

**First published:**

12/03/2024

[View](/ro/documents/conditions-member-states/pomalidomide-viatris-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_ro.pdf)

slovenčina (SK) (206.51 KB - PDF)

**First published:**

12/03/2024

[View](/sk/documents/conditions-member-states/pomalidomide-viatris-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_sk.pdf)

slovenščina (SL) (176.31 KB - PDF)

**First published:**

12/03/2024

[View](/sl/documents/conditions-member-states/pomalidomide-viatris-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_sl.pdf)

Suomi (FI) (141.11 KB - PDF)

**First published:**

12/03/2024

[View](/fi/documents/conditions-member-states/pomalidomide-viatris-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_fi.pdf)

svenska (SV) (168.81 KB - PDF)

**First published:**

12/03/2024

[View](/sv/documents/conditions-member-states/pomalidomide-viatris-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_sv.pdf)

## Product details

Name of medicine Pomalidomide Viatris Active substance Pomalidomide International non-proprietary name (INN) or common name pomalidomide Therapeutic area (MeSH) Multiple Myeloma Anatomical therapeutic chemical (ATC) code L04AX06

### Pharmacotherapeutic group

Immunosuppressants

### Therapeutic indication

Pomalidomide Viatris in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide. Pomalidomide Viatris in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

## Authorisation details

EMA product number EMEA/H/C/006195

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Viatris Limited

Damastown Industrial Park Mulhuddart Dublin 15 Ireland

Opinion adopted 14/12/2023 Marketing authorisation issued 16/02/2024 Revision 1

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Pomalidomide Viatris : EPAR - Procedural steps taken and scientific information after the authorisation

English (EN) (103.54 KB - PDF)

**First published:** 06/01/2025

[View](/en/documents/procedural-steps-after/pomalidomide-viatris-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Pomalidomide Viatris : EPAR - Public assessment report

Reference Number: EMA/21354/2024

English (EN) (1.45 MB - PDF)

**First published:** 12/03/2024

[View](/en/documents/assessment-report/pomalidomide-viatris-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Pomalidomide Viatris

Reference Number: EMA/CHMP/554066/2023

English (EN) (131.12 KB - PDF)

**First published:** 15/12/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-pomalidomide-viatris_en.pdf)

#### News on Pomalidomide Viatris

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 December 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-december-2023) 15/12/2023

**This page was last updated on** 06/01/2025

## Share this page

[Back to top](#main-content)